Panel: Combination Therapies at 10:05 AM, April 29, with Grant
McArthur
Conference Runs April 28–30, 2016, in Vatican City
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.pvct.com),
a clinical-stage oncology and dermatology biopharmaceutical company
("Provectus" or “The Company”), today announced that it will be
participating in a panel discussion at Cellular Horizons: The Third
International Conference on the Progress of Regenerative Medicine and
its Cultural Impact. The conference will be held April 28-30, 2016, in
Vatican City, and hosted by the Vatican’s Pontifical Council for
Culture, The Stem For Life Foundation and the STOQ (Science, Theology
and the Ontological Quest) Foundation.
Peter Culpepper, interim CEO and COO of Provectus, said, “We are deeply
honored to be participating in this global conference and to be doing so
with one of our investigators, Grant McArthur, who leads investigations
into new cancer treatments that control cell growth, division and
differentiation.
“Provectus and its investigators are engaged in multiple studies that
are of relevance to the conference. Our phase 3 study of intralesional
PV-10 as a stand alone treatment of locally advanced cutaneous melanoma
addresses early-stage advanced melanoma, while our study of IL PV-10 in
combination with a systemic immune checkpoint inhibition for treatment
of metastatic melanoma, specifically Merck’s Keytruda (pembrolizumab),
addresses more advanced-stage melanoma.”
Mr. Culpepper concluded, “Finally, our research into the mechanism of
action for PV-10 suggests that there are treatments that harness the
body’s own disease fighting powers that could bring new tools to the
medical profession in treating many kinds of disease.”
“The Third International Conference on the Progress of Regenerative
Medicine and Its Cultural Impact will rally the world around a powerful
idea ─ that the cells of our bodies hold the potential to vanquish
disease, reduce global suffering and inspire hope for people around the
world living with illness. We will discuss immunotherapies for
autoimmune diseases and cancer and explore how combination therapies
will allow maximizing the immune system for more effective therapy,”
said Dr. Robin Smith, President of The Stem For Life Foundation.
About The Stem For Life Foundation
The Stem For Life Foundation (SFLF) is the educational and
advocacy subsidiary of The Cura Foundation and is devoted to fostering
global awareness of the potential for regenerative medicine to treat and
cure a range of deadly diseases and debilitating medical conditions, as
opposed to merely treating their symptoms. The Foundation stands at the
forefront of a fundamental shift away from traditional drug treatment in
favor of amplifying the body’s natural repair mechanisms to vanquish
disease. For more information on The Stem For Life Foundation, please
visit http://www.stemforlife.org.
To follow the Vatican event on Twitter, please join the conversation @StemForLife
or via the hashtag #UNITETOCURE.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing oncology
and dermatology therapies. PV-10, its novel investigational drug for
cancer, is designed for injection into solid tumors (intralesional
administration), thereby reducing potential for systemic side effects.
Its oncology focus is on melanoma, breast cancer and cancers of the
liver. The Company has received orphan drug designations from the FDA
for its melanoma and hepatocellular carcinoma indications. PH-10, its
topical investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has completed
Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of
PH-10 as a topical treatment for atopic dermatitis and psoriasis.
Information about these and the Company's other clinical trials can be
found at the NIH registry, www.clinicaltrials.gov.
For additional information about Provectus, please visit the Company's
website at www.pvct.com or
contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking
statements" as defined under U.S. federal securities laws. These
statements reflect management's current knowledge, assumptions, beliefs,
estimates, and expectations and express management's current views of
future performance, results, and trends and may be identified by their
use of terms such as "anticipate," "believe," "could," "estimate,"
"expect," "intend," "may," "plan," "predict," "project," "will," and
other similar terms. Forward-looking statements are subject to a number
of risks and uncertainties that could cause our actual results to
materially differ from those described in the forward-looking
statements. Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking statements
include those discussed in our filings with the Securities and Exchange
Commission (including those described in Item 1A of our Annual Report on
Form 10-K for the year ended December 31, 2015) and the following:
-
our determination, based on guidance from the FDA, whether to proceed
with or without a partner with the fully enrolled phase 3 trial of
PV-10 to treat locally advanced cutaneous melanoma and the costs
associated with such a trial if it is necessary to complete (versus
interim data alone);
-
our determination whether to license PV-10, our investigational drug
product for melanoma and other solid tumors such as cancers of the
liver, if such licensure is appropriate considering the timing and
structure of such a license, or to commercialize PV-10 on our own to
treat melanoma and other solid tumors such as cancers of the liver;
-
our ability to license PH-10, our investigational drug product for
dermatology, on the basis of our phase 2 atopic dermatitis and
psoriasis results, which are in the process of being further developed
in conjunction with mechanism of action studies; and
-
our ability to raise additional capital if we determine to
commercialize PV-10 and/or PH-10 on our own, although our expectation
is to be acquired by a prospective pharmaceutical or biotech concern
prior to commercialization.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160427005243/en/
Copyright Business Wire 2016